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Abstract
Objective: Invasive pneumococcal disease (IPD) is a leading cause of morbidity and mortality in HIV-infected African adults.
CD4 T cell depletion may partially explain this high disease burden but those with relatively preserved T cell numbers are
still at increased risk of IPD. This study evaluated the extent of pneumococcal-specific T cell memory dysfunction in
asymptomatic HIV infection early on in the evolution of the disease.
Methods: Peripheral blood mononuclear cells were isolated from asymptomatic HIV-infected and HIV-uninfected Malawian
adults and stained to characterize the underlying degree of CD4 T cell immune activation, senescence and regulation.
Pneumococcal-specific T cell proliferation, IFN-c, IL-17 production and CD154 expression was assessed using flow cytometry
and ELISpot.
Results: We find that in asymptomatic HIV-infected Malawian adults, there is considerable immune disruption with an
increase in activated and senescent CD4
+CD38
+PD-1
+ and CD4
+CD25
highFoxp3
+ Treg cells. In the context of high
pneumococcal exposure and therefore immune stimulation, show a failure in pneumococcal-specific memory T cell
proliferation, skewing of T cell cytokine production with preservation of interleukin-17 but decreased interferon-gamma
responses, and failure of activated T cells to express the co-stimulatory molecule CD154.
Conclusion: Asymptomatic HIV-infected Malawian adults show early signs of pneumococcal- specific immune dysregulation
with a shift in the balance of CD4 memory, T helper 17 cells and Treg. Together these data offer a mechanistic
understanding of how antigen-specific T cell dysfunction occurs prior to T cell depletion and may explain the early
susceptibility to IPD in those with relatively preserved CD4 T cell numbers.
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Introduction
Worldwide, Streptococcus pneumoniae is a leading cause of pneumo-
nia, bacteremia and meningitis, resulting in approximately 1.1
million deaths annually[1,2]. Sub-Saharan Africa has a dispropor-
tionate share of this burden of invasive pneumococcal disease (IPD),
which in 85–90% of adults is HIV-associated[3]. Even in the early
stages, when CD4 counts are relatively preserved, HIV-infected
individuals are up to 20 times more likely to develop IPD[4,5].
In healthy people, the predominance of pneumococcal disease in
children under 5 years and the fall in the prevalence of nasopharyngeal
carriage in early adulthood suggest that there is acquisition of natural
anti-pneumococcal immunity with age. Previously, protective immu-
nity to the pneumococcus in humans was thought to be largely
mediated by antibodies to the pneumococcal polysaccharide cap-
sule[6], however, we and others have described naturally acquired B
and T cell immunity to a variety of pneumococcal proteins[7,8].
Studies of colonization, antibody acquisition and the relationship with
otitis media suggest that naturally-induced antibodies to pneumococcal
protein antigens are protective against disease[9,10]. Pneumococcal
specific T cell responses promote the maturation of these B cell
responses. In addition, recent data suggests that T-helper 1 (Th1) and
Th17 cells may facilitate the clearance of pneumococcal colonization
within the nasopharynx[11,12] and that Th1 cells control the
multiplication of bacteria following dissemination[13,14].
In HIV infection, it is now widely recognized that the decline of
CD4 T cells is not equally distributed throughout lymphoid tissues
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inflammation’’ such as mucosal surfaces[15]. Given that Strepto-
coccus pneumoniae is found in the nasopharynx of up to 28% of HIV
infected African adults[16], it is logical that depletion of
pneumococcal-specific mucosal T cells predispose HIV-infected
individuals to invasive disease. However, the observation that
individuals with relatively preserved peripheral CD4 T cells are
still susceptible to IPD suggests that either this compromised T cell
immunity is largely compartmentalized within the upper respira-
tory tract (URT) mucosa, or that more subtle functional defects in
pneumococcal-specific T cell memory and regulation occur early
in the evolution of HIV disease.
In this study conducted in an African population, we show that in
asymptomatic HIV infection (WHO stage I) there is considerable
immune activation with increased proportions of senescent and
Treg cells. We find that, even where there is high pneumococcal
exposure, pneumococcal-specific effector memory interferon–gam-
ma (IFN-c) responses are decreased and that replenishment of this
pool may be hindered by poor proliferative capacity of pneumo-
coccal specific central memory (TCM) T cells. These defects are
associated with a shift in the balance of interleukin (IL)-17 and IFN-
c responses, and failure of activated T cells to express the co-
stimulatory molecule CD154 showing that circulating CD4 T cells
already show high degrees of immune dysfunction.
Materials and Methods
Ethical approval
The collection of samples and the research described was
approved by The College of Medicine Research Ethics Committee,
Malawi (P.03/08/626, P.01/09/717) and The Liverpool School of
Tropical Medicine Research Ethics Committee (08.41, 08.61).
Subjects
85 adults were recruited from the voluntary counseling and
testing clinic (VCT) at Queen Elizabeth Central hospital in
Blantyre, Malawi following written informed consent. Of the 85
subjects; 31 were healthy controls confirmed by two HIV rapid
antibody tests Uni-gold (Trinity Biotech plc, Bary, Ireland) and
Determine (Abbott Laboratories, Minato-ku, Tokyo Japan) and 54
subjects were asymptomatic HIV-infected adults (WHO stage 1).
Peripheral blood CD4 T cell counts were determined by flow
cytometry using FacsCount (Becton Dickinson, Oxford, UK).
Assessment of pneumococcal colonization
Nasopharyngeal swabs were obtained and immediately placed
into a vial of skim milk-tryptone-glucose-glycerol (STGG)
transport medium[8]. When required these were thawed and
plated on gentamicin blood agar for the isolation of S. pneumoniae.
Pneumococci were identified by morphologic characteristics and
optochin susceptibility.
Antigens
Pneumococcal culture supernatants were prepared from a
standard encapsulated type 2 (D39) S. pneumonia strain and an
isogenic pneumolysin-deficient mutant (Ply-; was kindly provided
by James Paton)[17]. Bradford protein assay was used to measure
the concentration of the concentrated pneumococcal culture
supernatant (CCS). The concentrated culture supernatants were
heat-inactivated at 56uC for 30 min to reduce toxic effects of
pneumococcal proteins (in the absence of heat inactivation toxicity
frequently inhibited proliferative capacity). M. tuberculosis purified
protein derivative (PPD RT49) was obtained from Statens Serum
Institut. Influenza antigens were derived from dialyzed inactive
trivalent split virion influenza vaccine (EnziraH2006/2007)
obtained from Aventis-Pasteur. Phytohemagglutinin (PHA), phor-
bol 12-myristate 13-acetate (PMA) and ionomycin were obtained
from Sigma-Aldrich, St-Louis, MO.
Cells and reagents
Peripheral blood mononuclear cells (PBMC) were isolated from
blood by 25 min centrifugation at 400 g on a density-gradient
(Histopaque, Sigma). PBMC were harvested, washed in hanks
balanced salt solution (HBSS, Invitrogen, Paisley, UK) at 400 g for
10 min, and resuspended in complete RPMI (RPMI-1640 with
100 U/ml penicillin, 0.1 mg/ml streptomycin, 4 mM LL-gluta-
mine and 10 mM HEPES buffer). PBMC were counted using
0.4% (wt/vol) trypan blue (Sigma), reconstituted in complete
RPMI at a concentration of 1610
6cells/ml; with a final concen-
tration of 2% (vol/vol) heat-inactivated human AB serum
(National Blood Services, Blantyre) and incubated at 37uCi n
presence of 5% CO2.
Phenotyping of T cell subsets
20 ml of whole blood was stained at room temperature in the dark
for 10min with differing combinations of specific antibodies con-
jugated to selected fluorochromes: CD3, CD38 and CD25 conjugated
to fluorescein isothiocyanate (FITC), CD4, CD8 conjugated to
peridinin chlorophyll protein (Percp), CD45RA phycoerythrin (PE),
CCR7 allophycocyanin (APC) (all from BD Bioscience, San Jose, CA),
PD1-PE and Foxp3-PE (eBioscience, San Diego, CA). After surface
staining, red blood cells were lysed with 1X Facs lysing solution (BD).
Intracellular staining for Foxp3 was performed after fixation and
permeabilization with Foxp3 staining buffer set as per manufactures
instructions (eBioscience). For all flow cytometric assays, 10,000–
60,000 events were acquired within the lymphocyte gate on either
FACSCalibur (BD Biosciences, UK) or CyAn ADP 9 Color (Beckman
Coulter, USA) flow cytometers. Analysis was performed with FlowJo
(TreeStar, Ashland, OR).
Ex vivo enzyme-linked immunosorbent spot (ELISPOT)
assay
Freshly isolated PBMC were assayed for cells producing IFN-c,
using an ELISPOT assay as previously described[8]. SFC were
quantified with an automated ELISPOT reader (AID), and data
were expressed as SFC per million PBMC.
Proliferation assay
Peripheral blood mononuclear cells were labeled with 2.5 mm
carboxyfluorescein diacetate 5,6 succinimidyl ester (CFSE) dye
(Invitrogen) to identify the dividing T cell population. Labeled cells
were cultured at 1610
6cells/ml in a 48-well plate with WT CCS
(8 mg/ml), Ply-CCS (8 mg/ml), PPD (10 mg/ml), influenza (0.9 mg/
ml), PHA(10 mg/ml)ormediaonly, for8 days. Cellswereharvested
and stained with anti-CD4-APC (BD Biosciences) and assessed by
flow cytometry. Antigen specific T cell proliferation was expressed
as the percentage of CD4
+cells. In a subset of individuals, PBMC
were further stimulated with PMA (100 ng/ml) and ionomycin
(500 ng/ml) on day 8 for 6h and pneumococcal specific CFSElow
proliferating cells were evaluated for IFN-c and IL-17 production
using intracellular cytokine staining. Brefeldin A (10 mg/ml) (Sigma)
was added 1h after polyclonal stimulation to block the secretion of
cytokines. Cells were harvested and stained with anti-CD4-PerCp,
CD8-ECD (Beckman Coulter) and CD3-APC-H7 (BD Bioscience)
for 10 min. After washing with PBS, cells were permeabilized and
fixed using cytofix/cytoperm (BD Bioscience) as per manufactures
instructions. Cells were then incubated for 30 min at 4uC with anti-
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washed with 1x Perm Wash (BD Bioscience), resuspended and
analyzed by flow cytometry.
Detection CD154 expression as measured by surface
mobilization assay
Total PBMC 1.5–2610
6 were resuspended in 200 ml complete
RPMI and plated in a 96-well plate. Anti-CD154-PE antibody was
added prior to antigen stimulation to capture the surface and
transient expression of CD154 as previously described[18]. The
cells were stimulated with WT CCS (8 mg/ml), Ply-CCS (8 mg/
ml), M. tuberculosis PPD (4 mg/ml), PHA (10 mg/ml) or media only
for 16hs. After stimulation, cells were harvested, washed and
surface-stained with anti-CD3-FITC, CD4-PerCP, CD69-APC
and CD154-PE (BD Biosciences) for 15min at 4uC in the dark.
Cells were washed with 1ml PBS at 400g for 5 minutes,
resuspended and analyzed by flow cytometry
Cytokine profiles in cell culture supernatants
Cell culture supernatants were analyzed for IL-10, IL-2, tumor
necrosis factor–alpha (TNF-a), and IFN-c, using the human bioplex
cytokine assay (Bio-Rad, Hercules, CA, USA) according to the
manufacturer’s instructions. Beads were read on the Bio-Plex 100
suspension array system (Applied Cytometry), and data were analyzed
using Bio-Plex Manager software, version 3.0. The concentration of
IL-17A was measured by IL-17A ELISA (eBioscience), read on Opsys
MR plate-reader and analyzed using Revelation QuickLink software
(Dynex Technologies, Virginia, USA).
Statistical analysis
Statistical analyses and graphical presentation were performed
using Graphpad Prism 5 (Graphpad). Non-parametric data were
analyzed using the Mann-Whitney U test. Results are given as
means with standard error of the mean (for parametric tests) or as
medians with ranges (for non-parametric tests). Differences were
considered significant if P#0.05.
Results
Demographic characteristics
31healthyadult controls(median age 33years[range23–53]) and
54 asymptomatic WHO stage 1 HIV-infected adults (median age
31years [range 18–58]) were recruited (Table.1). All participants
were anti-retroviral therapy (ART) and co-trimoxazole naive, and
had no recent history of severe respiratory infection or TB. Healthy
controls and those infected with HIV were similar in age, sex
distribution and prevalence of pneumococcal carriage. The median
CD4 count amongst the HIV-infected participants was 252 (range
7-913cells/ml).Foranalysispurposes,HIVinfectedindividualswere
stratified by peripheral CD4 count (CD4$500, CD4 350–500 and
CD4#350cells/ml). WHO currently recommends the commence-
ment of ART when CD4,350cells/ml but this had not been
implemented in Malawi at the time of the study[19].
Effector memory, senescent and regulatory CD4 T cells in
asymptomatic HIV infected Malawian adults
HIV infection is associated with chronic activation of the immune
system[20] with an early depletion of memory T cells[21], increased
senescent CD4 T cells expressing programmed death 1 (PD-1)[22] and
mucosal Tregs[23]. In contrast to industrialized countries, individuals
in a resource-poor setting are under increased immune pressure from
parasitic diseases such as malaria and micronutrient deficien-
cies[24,25]. We therefore investigated the degree of immune disruption
caused by HIV in a population of HIV-infected African adults.
We compared the proportional balance of TEM (CD4
+CCR7
2
CD45RA
2),TCM (CD4
+CCR7
+CD45RA
2), naı ¨ve T cells, regulatory
(CD4
+CD25
highFoxp3
+) and senescent (CD4
+CD38
+PD-1
+) T cells in
peripheral blood of healthy controls and HIV-infected individuals[26].
Ex vivo flow cytometric analysis showed a decrease in absolute
number of TCM and naive cells in individuals with robust CD4
counts 350-500cells/ml. In contrast, TEM were depleted only in
those with very low CD4 counts #350cells/ml (data not shown).
The preferential depletion of TCM resulted in an imbalance in the
proportion of circulating TEM (CD4
+CCR7
2CD45RA
2) vs. TCM
(CD4
+CCR7
+CD45RA
2) cells in HIV-infected adults (Fig. 1ab).
The proportion of naive CD4
+CCR7
+CD45RA
+ T cells was
comparable between healthy controls and HIV-infected individ-
uals (Fig. 1c). This relative increase in TEM cells was coupled with
an increase in CD4
+CD38
+ T cells expressing the co-inhibitory
molecule PD-1, which is associated with immune activation and
senescence in both naı ¨ve and memory T cells[27](Fig. 1d). These
findings show that HIV infection drives persistent immune
activation[28] and eventual exhaustion early on in asympto-
matic HIV-infection in a African population. Furthermore,
CD4
+CD25
highFoxp3
+ Treg were proportionally increased in
those infected with HIV (Fig. 1e) thus altering the ratio of Treg: T
cell responders.
Antigen-specific IFN-c effector responses in HIV infection
HIV targets recently activated mucosal effector cells in the gut
early on in disease, partly due to their high expression of HIV co-
receptors[15,29]. To evaluate whether HIV infection leads to
Table 1. Patient demographics, age, sex, median CD4 count cells/ml blood, S. pneumoniae carriage, WHO clinical stage.
HIV-
n=31
HIV+
n=54
HIV+ $500
n=10
HIV+ 350-500
n=14
HIV+ #350
n=30
Age 33 (23–53) 31 (18–58) 29 (21–47) 28 (23–40) 32 (18–58)
Female 32% 46% 87% 50% 24%
Male 68% 54% 13% 50% 76%
CD4 count (cells/ml) 853 *252 695 403 192
CD4 range (cells/ml) (444–1323) (7–913) (549–913) (352–495) (7–292)
Carriage 16% 14% 13% 14% 13%
WHO Stage n/a Stage 1 Stage 1 Stage 1 Stage 1
Not available (NA). *Significance determined by Mann Whitney U, p=#0.05 (HIV- vs HIV+).
doi:10.1371/journal.pone.0025610.t001
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within the URT, pneumococcal TEM IFN-c responses were
evaluated in comparison to other respiratory pathogens, M.
tuberculosis and influenza (not typically associated with prolonged
asymptomatic mucosal carriage). The number of IFN-c producing
cells responding to WT CCS was low but detectable in healthy
controlsandwasrelativelywellpreservedinHIVinfection(Fig.2a).
To assess the potential immunomodulatory effect of pneumoly-
sin[30], Ply
2CCS was used to stimulate IFN-c responses. In healthy
controls, there were more IFN-c producing cells in response to
Ply
2CCS as compared to WT CCS but a decreased pneumococcal
IFN-c response was seen in HIV-infected individuals (Fig. 2b).
IFN-c producing cells were also decreased in response to
M. tuberculosis PPD (Fig. 2c) and influenza antigens (Fig. 2d)i n
HIV-infected persons. We have previously shown that that
ex vivo IFN-c pneumococcal responses are derived from
CD4
+CD45RO
+CCR7
2 effector memory cells[8], thus a lack of
IFN-c responses reflects either the depletion or an impairment of
TEM function.
HIV infection impairs antigen-specific CD4 T cell
proliferation
To reconstitute the antigen specific TEM pool, TCM must
rapidly expand, differentiate and migrate to effector tissue
sites[26]. We therefore evaluated the proliferative capacity of T
cells in response to WT, Ply
2 CCS, M. tuberculosis PPD, influenza
Figure 1. Baseline phenotyping of peripheral blood CD4 T cells. Proportional representation of circulating TEM (CD4
+CCR7
2CD45RA
2)( a),
TCM (CD4
+CCR7
+CD45RA
2)( b), naı ¨ve T cells (CD4
+CCR7
+CD45RA
+)( c), regulatory (CD4
+CD25
highFoxp3
+)( d) and senescent (CD4
+CD38
+PD-1
+)( e) CD4
T cells using flow cytometry in healthy controls (n=8–14) and HIV-infected groups ($500 (n=2–10) 3502500 (n=4-9) #350 (n=17–19) CD4 T cells/
ml blood). Black horizontal bars represent median values of CD4 subsets. Statistical significance was analyzed by the Mann Whitney U test.
doi:10.1371/journal.pone.0025610.g001
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found impaired proliferation in response to WT CCS (Fig. 3a),
Ply
2CCS (Fig. 3b), M. tuberculosis PPD (Fig. 3c) and influenza
(Fig. 3d) compared to healthy controls, whilst intrinsic prolifer-
ative capacity to PHA remained intact (Fig. 3e). These data
suggest that the cognate interaction required for the renewal or
maintenance of antigen-specific CD4 proliferating T cells is
impaired.
Failure to upregulate CD154 (CD40L) on activated CD4 T
cells
CD40 dependent impairment of CD4 T cell CD154 expression
has been described in HIV infection[31] and reduced CD40L-
CD40 interaction may contribute to poor pneumococcal-specific T
cell proliferation and/or effector function. We therefore evaluated
whether recently activated CD4
+CD69
+ T cells responding
specifically to pneumococcal and tuberculin antigens were capable
of upregulating this critical co-stimulatory molecule. In HIV
infection, T cell activation (CD4
+CD69
+) was reduced in response
to M. tuberculosis PPD butnot in response to the pneumococcus(data
not shown). Nevertheless the expression of CD154 on activated T
cells was impaired in response to WT, Ply
2CCS and M. tuberculosis
PPD suggesting a specificdecrease in CD154 regulation that didnot
necessarily follow a generalized decrease in cellular activation and
CD69 upregulation(Fig. 4). The finding that CD154wasexpressed
in response to PHA (which activates T cells in the absence of
CD40
+APC[32]) (Fig. 4d) shows that the defect is not intrinsic to
the T cell, as suggested by others[33], but is likely to occur during a
cognate interaction with APCs.
Preservation of pneumococcal-specific IL-17 but
impairment of IFN-c production
Th1 and Th17 cells have been shown to be important in
facilitating the clearance of the pneumococcus[11,12] and controlling
multiplication of bacteria following dissemination[13,14]. We have
suggested that these responses are moderated by Treg in healthy
populations[34]. Th1 cells classically produce IFN-c,T N F - a and IL-
2, Th17 cells produce IL-17 and a subset of Treg produce IL-10[35].
To investigate whether an increase in IPD risk is associated with a
selective loss of either Th17 or Th1subsets or the over-representation
of Tregs, we investigated the balance of these cytokines in cell culture
supernatants from pneumococcal 8 day stimulation assays. In healthy
controls, stimulation with WT and Ply
2CCS resulted in the
production of IFN-c (Fig. 5a)a n dI L - 1 7( Fig. 5b). In HIV infection,
IFN-c production was greatly reduced, whilst IL-17 production was
not significantly different to healthy controls. Concentrations of IL-
10, TNF-a, and IL-2 were similar between HIV-infected individuals
and healthy controls (data not shown). As cytokine concentrations are
influenced by the number and proliferative capacity of cells in culture,
we evaluated intracellular IFN-c and IL-17 from proliferating
pneumococcal-specific T cells using flowcytometry(Fig. 5c). In
HIV infection, proportionally less pneumococcal-specific T cells
Figure 2. Antigen-specific ex vivo IFN-c responses. (a) in response to a wild-type Streptococcus pneumoniae strain (WT), (b) an isogenic
pneumolysin (Ply)–deficient mutant (Ply-), (c) M. tuberculosis PPD and (d) influenza for 16 hours by IFN-c enzyme-linked immunosorbent spot
(ELISPOT) stimulation. Collated data from controls (n=12–15) and those infected with HIV ($500 (n=7–10) 350-500 (n=9–11), #350 (n=14–17) CD4
T cells/ml). Black horizontal bars represent median values of total antigen specific responses above background. Statistical significance was analyzed
by the Mann Whitney U test.
doi:10.1371/journal.pone.0025610.g002
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PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e25610Figure 3. Proliferative capacity of antigen–specific CD4+ T cells. (a) in response to a wild-type Streptococcus pneumoniae strain (WT), (b)an
isogenic pneumolysin (Ply)–deficient mutant (Ply_), (c) M. tuberculosis PPD (d) influenza (e) phytohemagglutinin (PHA) using flow cytometry.
Collated data from controls (n=18–31) and those infected with HIV ($500 (n=627), 350–500 (n=729), #350 (n=15216) CD4 T cells/ml blood).
Black horizontal bars represent median values of total antigen specific responses above background. Statistical significance was analyzed by the
Mann Whitney U test. (f) Representative flow cytometric data demonstrating CD4+ T cell proliferative responses in media only, M. tuberculosis PPD,
influenza and pneumococcal antigens. The percentage indicated in the upper-left quadrant represents the cell population that proliferated over the
8-day culture period.
doi:10.1371/journal.pone.0025610.g003
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IFN-c/IL-17 double positive responses were increased(Fig. 5d&e).
In contrast, influenza and M. tuberculosis-specific T cells produced no
IL-17 but IFN-c was consistently decreased in those infected with
HIV (data not shown).
Discussion
Invasive pneumococcal disease remains an important cause of
HIV-related death in Sub-Saharan Africa (SSA), even in the era of
widespread ART roll-out[36]. For the effective design and
evaluation of both existing and novel pneumococcal vaccines for
implementation in SSA adult populations, pneumococcal immu-
nity must be studied where disease burden is greatest and where
poor nutrition and parasitic infections such as malaria compound
disease susceptibility in HIV-infected individuals[24]. Our inves-
tigations have therefore targeted African adults with asymptomatic
HIV infection and relatively preserved CD4 counts to iden-
tify which immunological processes are affected early in the
progression of the disease. We show considerable immune dys-
function with a skew towards TEM and activated CD4 T cells
expressing the co-inhibitory senescence marker PD-1. In the
context of this immune activation and exhaustion, we show
reduced pneumococcal-specific IFN-c effector responses and
impaired TCM proliferative function, thus limiting the capacity
to replenish the effector pool. Whilst IL-17 responses appeared to
be preserved in asymptomatic HIV infection, IFN-c production
was greatly reduced in dividing T cells. Furthermore, pneumo-
coccal-specific activated T cells failed to upregulate CD154
(CD40L), a key mediator of T cell- B cell/APC cross talk[37].
Together these data implicate defects in immune regulation, T-
helper function and T-B cell signaling with a shift in the normal
balance of Th1 and Th17 cells in the early phases of disease
progression. Factors such as poor epithelial barrier integrity[38]
and reduced innate antimicrobial defensins[39] may further
exacerbate this immune imbalance[24].
Given the intensity of pneumococcal colonization in African
populations[8] and our data showing localized anti-pneumococcal
mucosal immune responses[7], we had expected that activated
pneumococcal-specific cells would be preferentially depleted by
HIV, possibly through HIV co-receptors such as the mucosal
homing receptor a4b7[29] or CD25 expression which is linked to
enhanced HIV replication and cellular apoptosis[40]. Interesting-
ly, we found no evidence for selective depletion of pneumococcal-
specific T cells when compared with immunity to M. tuberculosis
and influenza virus, respiratory pathogens not typically associated
with commensalism at the mucosal surface. There are several
potential explanations for this apparently more generalized
memory T cell depletion, including mucosal compartmentaliza-
tion of pneumococcal-specific T cell depletion and HIV infection
of all resting memory T cells regardless of specificity[41]. We
suggest that even though antigen exposure is less common, the
inflammatory nature of the immune response to influenza and
mycobacteria produces a high frequency of central memory T cells
which are prone to HIV infection and depletion. In fact,
Geldmacher et al have recently demonstrated that TB-specific
CD4 TCM expressing IL-2 were preferentially depleted early on in
HIV infection (6212 months following HIV seroconversion) as
compared to CMV-specific CD4 T cells[42]. In contrast, the
pneumococcus, a highly adapted commensal, avoids activation of
adaptive immunity at the mucosal surface by evading recognition,
inducing tolerance or regulation[43,44]. Thus, although encounter
is frequent, pneumococcal-specific T cells are less vigorously
targeted for HIV-mediated depletion.
Murine models have demonstrated that effective clearance of
colonizing pneumococci requires a population of Th17 cells and
the recruitment of neutrophils[11,12]. Potentially a preferential
loss of Th17 cells in the URT could cause an increase in the
Figure 4. CD154 expression on CD4+CD69+ T cells. (a) in response to a wild-type Streptococcus pneumoniae strain (WT), (b) an isogenic
pneumolysin (Ply)–deficient mutant (Ply_), (c) M. tuberculosis PPD and (d) phytohemagglutinin (PHA) in HIV- controls (n=19-20) and those infected
with HIV ($500 (n=8), 350–500 (n=10), #350 (n=21) CD4 T cells/ml blood). Black horizontal bars represent median values of total antigen specific
responses above background. Statistical significance was analyzed by the Mann Whitney U test.
doi:10.1371/journal.pone.0025610.g004
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thus increase the risk of bacterial dissemination. Interestingly, we
find no increase in pneumococcal carriage in asymptomatic
Malawian adults with HIV infection and show that despite other
antigen-specific defects in T cell memory, IL-17 production to
pneumococcal antigens is preserved, at least in the periphery.
However, our data does raise the alternative possibility that
although control of pneumococcal colonization is unaffected in
this population, the risk of disease is increased because of failure to
control pneumococcal invasion and dissemination following
colonization, in part due to impaired IFN-c production. Our
findings show that T cells producing IFN-c decline before those
that produce IL-17 thereby severely disabling arms of the immune
response that are enhanced by IFN-c, such as B cell isotype
switching and macrophage function[13,14]. We propose that poor
T cell IFN-c responses coupled with defective pneumococcal-
specific CD154 expression fails to enhance macrophage phagocy-
tosis and microbial killing when recruited to sites of tissue invasion.
Furthermore, CD154 deficient T cells homing to B cell follicles
will fail to facilitate B cell production of pneumococcal-specific
antibodies[45].
Several studies have shown that the induction of CD154 is
decreased in HIV-1-infected individuals and it is noteworthy that
chimpanzees that are susceptible to chronic infection by HIV-1
but rarely develop subsequent immunodeficiency or disease
progression, retain their ability to upregulate CD154 in the
context of HIV[46]. In keeping with previous reports[47], we have
found that cross-linking of CD4 with a monoclonal antibody to
domain 1 also leads to inhibition of CD154 upregulation in
response to pneumococcal antigens (data not shown). We therefore
postulate that cross-linking of CD4 by HIV glycoproteins can
disrupt normal T cell signal transduction in the early stages of HIV
infection when viral load is high, thus providing another
mechanism for the impairment of CD154. Furthermore, the
proportional increase in regulatory T cells and an over-
representation of CD4
+CD38
+PD-1
+ T cells which are almost
certainly HIV-specific, may contribute to impaired effector IFN-c
production, T cell proliferation and T cell CD40L expression, by
indirectly perturbing DC function[23,48].
Demonstration of immune dysregulation of anti-pneumococcal
immunity even in patients with CD4 counts that exceed the
current threshold for commencing ART (,350cells/ml), coupled
Figure 5. IFN-c and IL-17 production. Concentration of (a) IFN-c, and (b) IL-17 in PBMC cell culture supernatants stimulated with wild-type
Streptococcus pneumoniae strain (WT), and an isogenic pneumolysin (Ply)-deficient mutant and media only from healthy controls (grey bars) (n=6)
and HIV-infected subjects (white bars) (n=9). Data are mean values 6 standard error of the mean. (c) Representative flow cytometric data of media
only, HIV- and HIV+ T cells producing IFN-c and IL-17 following WT CCS stimulation. CFSElow pneumococcal-specific proliferating T cells were
selectively gated and cytokines evaluated. (d) CFSElow pneumococcal specific T cell IFN-c and IL-17 production following WT and (e) Ply-CCS in HIV-
(black circles n=11) and HIV+ (white circles n=13217) individuals. Grey data points represent pneumococcal carriers (nasopharynx). Black horizontal
bars represent median values of total antigen specific responses above background. Statistical significance was analyzed by the Mann Whitney U test.
doi:10.1371/journal.pone.0025610.g005
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stimulation in HIV-infected Malawian adults has direct implica-
tions for the design and implementation of both ART and
protective vaccines. Early introduction of ART not only restores T
cell numbers but also improves T cell function[49]. It remains to
be determined whether the early T cell recovery results in a
reversal of the multiple T cell defects we observed and restores a
balanced pneumococcal specific-Th1:Th17 response. In view of
the encouraging efficacy of the pneumococcal conjugate vaccines
in high risk HIV adults[50] but their reliance on carrier protein-
induced T cell help, it will be necessary to assess whether this
success can be translated into long-term immune protection
against IPD or whether defects affecting T cell function and
regulation of immunity to the carrier protein leads to poorly
sustained immune memory.
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